|
China Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The China Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for China .
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Chinese pharmaceutical and healthcare industry.
Competitive intelligence, Chinese pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Chinese market.
The China Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s China Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Chinese pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on China to test other views – a key input for successful budgeting and strategic business planning in the Chinese pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Chinese Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in China .
- Exploit The Latest Competitive Chinese Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in China .
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
China Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
Chapter - SWOT Analysis |
| China Pharmaceuticals And Healthcare Industry SWOT |
| China Political SWOT |
| China Economic SWOT |
| China Business Environment SWOT |
Chapter - Pharmaceutical Business Environment Ratings |
| Table: Asia Pacific Pharmaceuticals & Healthcare Business Environment Rankings For Q209 |
| Limits of Potential Returns |
| Risks to Realisation of Returns |
Chapter - Market Summary |
Chapter - Regulatory Regime |
| Intellectual Property Issues |
| Counterfeit Activities |
| Pricing and Reimbursement |
| Advertising Sector |
| SFDA Scandal |
| Other Regulatory Developments |
Chapter - Industry Trends and Developments |
| Healthcare Sector |
| Hospital Sector |
| Epidemiology |
| Distribution Sector |
| Table: Top Ten Chinese Pharmaceutical Distributors In 2007 |
| Traditional Chinese Medicines |
| R&D Activity |
| Vaccine Sector |
| Clinical Trials Activity |
| Biotechnology Sector |
| Active Pharmaceutical Ingredients (APIs) |
| Pharmaceutical Equipment Sector |
Chapter - Industry Forecast Scenario |
| Overall Market Forecast |
| Table: China ''“ Drug Market Data And Forecasts, 2003-2013 |
| Table: Macroeconomic Indicators Used In BMI'''s Pharmaceutical Market Expenditure Model, 2003-2013 |
| Key Growth Factors ''“ Industry |
| Table: China ''“ Health Expenditure Data And Forecasts, 2003-2013 |
| Key Growth Factors ''“ Macroeconomic |
| Table: China - Economic Activity, 2006-2013 |
| Prescription Market Forecast |
| Table: China ''“ Prescription Drug Market Data And Forecasts (CNYmn unless otherwise stated) |
| OTC Market Forecast |
| Table: China ''“ OTC Market Data And Forecasts (US$mn unless otherwise stated) |
| Generics and Patented Market Forecasts |
| Table: China ''“ Generics And Patented Market Forecasts, 2003-2013 |
| Export/Import Forecasts |
| Table: China ''“ Pharmaceutical Trade Data And Forecasts, 2003-2013 (US$mn) |
| Medical Device Market Forecast |
| China: Medical Device Market Data And Forecasts, 2006-2012 (US$bn unless otherwise stated) |
| Other Healthcare Data Forecasts |
| Table: China ''“ Hospital Data Forecasts, 2005-2013 |
| Key Risks to BMI'''s Forecast Scenario |
Chapter - Competitive Landscape |
| Top Ten Chinese Pharmaceutical Companies In 2007 |
| Table: Top 10 OTC Companies In China By 2006 Sales |
| Top Ten Chinese Retail Pharmacy Chains In 2007 |
Chapter - Company Profiles |
| Leading Multinational Companies |
| GlaxoSmithKline |
| Pfizer |
| AstraZeneca |
| Merck KGaA |
| Sanofi-Aventis |
| Novartis |
| Roche |
| Merck & Co |
| Bayer Schering Pharma |
| Indigenous Manufacturers |
| North China Pharmaceutical Group Corporation (NCPC) |
| China Biopharmaceuticals Holdings (CBH) |
| Hubei Biocause Heilen Pharmaceutical |
| Aida Pharmaceutical Holdings |
Chapter - Country Snapshot: China Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Table: Rural/Urban Breakdown, 2005-2030 |
| Section 2: Education and Healthcare |
| Table: Education, 2002-2005 |
| Table: Vital Statistics, 2005-2030 |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
China Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
China's pharmaceutical market is the third largest in Asia Pacific, ahead of India and behind Japan. Combined sales of prescription products and over-the-counter (OTC) medicines reached US$36.99bn in 2008 – a 25.1% increase compared to the previous year. Drug spending accounts for 0.97% of GDP and annual per capita expenditure is US$27.50. Through to 2013, BMI is forecasting a compound annual growth rate (CAGR) of 14.92% for the overall pharmaceutical market.
It appears that intellectual property (IP) is being embraced by local drugmakers. It was revealed in April 2009 that the number of submissions and approvals for patent application from domestic players in China’s pharmaceutical industry were increasing at a faster rate than those from foreign parties, according to the State Intellectual Property Office (SIPO).
During 2009, Hebei province will pilot the separation of prescribing and dispensing of pharmaceuticals at hospitals. BMI believes the main beneficiaries of the change are generic drug manufacturers, pharmacy chains and, most importantly, patients.
Despite lingering questions of quality, efficacy and safety, the significance of traditional medicines in China cannot be overstated. These interventions have a firmly entrenched position in society and generate huge revenues for manufacturers, prescribers and retailers. Such is the popularity of ancient herbs in the world’s most populous country that sales of traditional Chinese medicines (TCMs) for the treatment of cardiovascular conditions exceed that recorded by Western pharmaceuticals in certain large cities. The country has had limited success in Western or allopathic pharmaceuticals, but this situation is changing. In March 2009, Beijing Healthstar Pharmaceutical started commercialising Su Ling (haemocoagulase agkistrodon). The haemostatic is derived from snake venom and will be patented soon.
Su Ling was approved by the State Food and Drug Administration (SFDA) in September 2008 as a 'Chinese self-developed Class I drug'. The global financial crisis has benefited the active pharmaceutical ingredient (API) sector. In February 2009 it was revealed that the prices of some Chinese APIs jumped in the first half of the month due to a spike in overseas demand and insufficient supply from scaled-back production.
|
China Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |